Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

Background: The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its efficacy. An emerging theory to explain intrinsic resistance to other anti-angiogenic drugs is ‘vessel co-option,’ ie, the ability of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuczynski, Elizabeth A., Yin, Melissa, Bar-Zion, Avinoam, Lee, Christina R., Butz, Henriett, Man, Shan, Daley, Frances, Vermeulen, Peter B., Yousef, George M., Foster, F. Stuart, Reynolds, Andrew R., Kerbel, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017954/
https://www.ncbi.nlm.nih.gov/pubmed/27059374
http://dx.doi.org/10.1093/jnci/djw030

Ejemplares similares

Ejemplares similares